Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 1/2010

01-01-2010

A New Model of Induced Experimental Systemic Lupus Erythematosus (SLE) in Pigs and Its Amelioration by Treatment with a Tolerogenic Peptide

Authors: Amir Sharabi, Molly Dayan, Heidy Zinger, Edna Mozes

Published in: Journal of Clinical Immunology | Issue 1/2010

Login to get access

Abstract

Introduction

Systemic lupus erythematosus (SLE) is characterized by a variety of autoantibodies and systemic clinical manifestations. A tolerogenic peptide, hCDR1, ameliorated lupus manifestations in mice models. The objectives of this study were to induce experimental SLE in pigs and to determine the ability of hCDR1 to immunomodulate the disease manifestations.

Results and Discussion

We report here the successful induction, by a monoclonal anti-DNA antibody, of an SLE-like disease in pigs, manifested by autoantibody production and glomerular immune complex deposits. Treatment of pigs with hCDR1 ameliorated the lupus-related manifestations. Furthermore, the treatment downregulated the gene expression of the pathogenic cytokines, interleukin (IL)-1β, tumor necrosis factor alpha, interferon gamma, and IL-10, and upregulated the expression of the immunosuppressive cytokine transforming growth factor beta, the antiapoptotic molecule Bcl-xL, and the suppressive master gene, Foxp3, hence restoring the expression of the latter to normal levels. Thus, hCDR1 is capable of ameliorating lupus in large animals and is a potential candidate for the treatment of SLE patients.
Literature
1.
Hahn BH. Overview of pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubious’ lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 46–53.
2.
Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol. 2005;25:123–40.CrossRefPubMed
3.
Theofilopoulos A. Murine models of lupus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Churchill Livingston; 1992. p. 121–94.
4.
Mendlovic S, Brocke S, Shoenfeld Y, Ben Basat M, Meshorer A, Bakimer R. Induction of a systemic lupus erythematosus like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A. 1988;85:2260–4.CrossRefPubMed
5.
Waisman A, Mendlovic S, Ruiz JP, Zinger H, Meshorer A, Mozes E. The role of the 16/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int Immunol. 1993;5:1293–300.CrossRefPubMed
6.
Waisman A, Mozes E. Variable regions of autoantibodies isolated from mice with experimental systemic lupus erythematosus. Eur J Immunol. 1993;23:1566–73.CrossRefPubMed
7.
Waisman A, Ruiz PJ, Israeli E, Eilat E, Kˆnen-Waisman S, Zinger H, et al. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci U S A. 1997;94:4620–5.CrossRefPubMed
8.
Eilat E, Zinger H, Nyska A, Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol. 2000;20:268–78.CrossRefPubMed
9.
Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2001;98:1148–53.CrossRefPubMed
10.
Zinger H, Eilat E, Meshorer A, Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZBxNZW)F1 mice via active suppression. Int Immunol. 2003;15:205–14.CrossRefPubMed
11.
Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol. 1995;7:689–96.CrossRefPubMed
12.
Luger D, Dayan M, Zinger H, Liu J-P, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol. 2004;24:579–90.CrossRefPubMed
13.
Parameswarran R, Ben David H, Sharabi A, Zinger H, Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol. 2009;131:223–32.CrossRef
14.
Rapoport MJ, Sharabi A, Aharoni D, Bloch O, Zinger H, Dayan M, et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol. 2005;117:262–70.CrossRefPubMed
15.
Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007;179:4979–87.PubMed
16.
Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-β. Proc Natl Acad Sci U S A. 2006;103:8810–5.CrossRefPubMed
17.
Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol. 2008;181:3243–51.PubMed
18.
Sthoeger ZM, Dayan M, Tcherniack A, Green L, Toledo S, Segal R, et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol. 2003;131:385–92.CrossRefPubMed
19.
Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol. 2004;137:513–20.CrossRefPubMed
20.
Sthoeger ZM, Sharabi A, Dayan M, Zinger H, Asher I, Sela U, et al. The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol. 2009;70:139–45.CrossRefPubMed
21.
Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev. 2003;196:176–96.CrossRefPubMed
22.
Saalmüller A, Werner T, Fachinger V. T-helper cells from naive to committed. Veterinary Immunol Immunopathol. 2002;87:137–45.CrossRef
23.
Rodrìguez-Carreòo, Lûpez-Fuertes L, Revilla C, Ezquerra A, Alonso F, Domìnguez J. Phenotypic characterization of porcine IFN-producing lymphocytes by flow cytometry. J Immunol Methods. 2002;259:171–9.CrossRef
24.
25.
26.
Kuo P, Bynoe MS, Wang C, Diamond B. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol. 1999;29:3168–78.CrossRefPubMed
27.
Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltzman Y, Kohen F, et al. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology. 1997;90:101–8.CrossRefPubMed
28.
Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin Exp Immunol. 1995;101:66–72.PubMedCrossRef
29.
Seery JP, Cattell V, Watt FM. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(β-o-methyl)-flu-oromethylketone. J Immunol. 2001;167:2452–5.PubMed
30.
Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol. 2006;119:146–55.CrossRefPubMed
31.
Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol. 1994;16:181–200.CrossRefPubMed
32.
Theofilopoulos AN, Lawson BR. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis. 1999;58(Suppl 1):I49–55.CrossRefPubMed
33.
Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1/T helper cell 2-type cytokines in disease. J Immunol. 1997;158:3009–16.PubMed
34.
Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2000;59:243–51.CrossRefPubMed
35.
36.
Trébéden-Nègre H, Weill B, Fournier C, Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol. 2003;33:1603–12.CrossRefPubMed
37.
Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152:3685–92.PubMed
38.
Ben-David H, Sharabi A, Parameswaran R, Zinger H, Mozes E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of IL-7, leading to apoptosis. Immunology. 2009;doi:10.​1111/​j.​1365-2567.​2009.​03109.​x.
39.
Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun. 2009;doi:10.​1016/​j.​jaut.​2009.​06.​002.
40.
Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998;160:2539–45.PubMed
41.
Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 1996;87:1439–45.PubMed
42.
Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.CrossRefPubMed
43.
44.
Horwitz DA. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther. 2008;10:227.CrossRefPubMed
45.
Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007;37:987–96.CrossRefPubMed
46.
Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology. 2007;121:248–57.CrossRefPubMed
47.
La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black × New Zealand White) F1 mice suppress in vitro production of antibodies to DNA. J Immunol. 2004;173:3542–8.PubMed
48.
Hahn BH, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58:2488–97.CrossRefPubMed
49.
Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005;174:3247–55.PubMed
50.
Kang HK, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007;178:7849–58.PubMed
51.
Sela U, Sharabi A, Dayan M, Hershkoviz R, Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology. 2008;128:e395–405.CrossRefPubMed
52.
Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun. 2009;33:77–82.CrossRefPubMed
Metadata
Title
A New Model of Induced Experimental Systemic Lupus Erythematosus (SLE) in Pigs and Its Amelioration by Treatment with a Tolerogenic Peptide
Authors
Amir Sharabi
Molly Dayan
Heidy Zinger
Edna Mozes
Publication date
01-01-2010
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2010
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-009-9326-4

Other articles of this Issue 1/2010

Journal of Clinical Immunology 1/2010 Go to the issue

OriginalPaper

Elevated Production of B Cell Chemokine CXCL13 is Correlated with Systemic Lupus Erythematosus Disease Activity

OriginalPaper

Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus

OriginalPaper

IGF-I Stimulates In Vivo Thymopoiesis After Stem Cell Transplantation in a Child with Omenn Syndrome

OriginalPaper

Clinical Characteristics and Genotype-phenotype Correlation in 62 Patients with X-linked Agammaglobulinemia

OriginalPaper

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

OriginalPaper

Differential Deposition of C4d and MBL in Glomeruli of Patients with ANCA-Negative Pauci-Immune Crescentic Glomerulonephritis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits